Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss
NCT07492160Phase 2Recruiting
- Sponsor
- Jefferson Drapkin
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lactation comparing Cabergoline with Placebo (2 arms). Primary endpoint: Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss. Started Mar 2026; status: recruiting.
02
Drugs
cabergoline
03
Conditions
lactation
Beyond the preview
Go deeper on NCT07492160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492160.